Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PKCT study of doxorubicin pharmacokinetics during antiretroviral switch to raltegravir in HIV-associated lymphoma
2010-023749-30Phase 4Completed
- Sponsor
- Fondazione Centro San Raffaele
- Start
- Mar 2012
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of doxorubicin and raltegravir in lymphoma and human immunodeficiency virus infection (HIV) (2 arms), sponsored by Fondazione Centro San Raffaele. Primary endpoints: Area under the curve of doxorubicin with interacting antiretroviral therapy and Area under the curve of doxorubicin after switch to raltegravir. Started Mar 2012; status: completed.
02
Drugs
doxorubicinraltegravir
03
Conditions
lymphomahuman immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2010-023749-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023749-30.